


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**52 RESEARCH RESULTS WILL BE PRESENTED AT**  
**2024 ASCO ANNUAL MEETING**

The board of directors (the “**Board**”) of the Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announced that the Group’s category 1 innovative drugs “Anlotinib (small molecule multi-targeting tyrosine kinase inhibitor)”, “Efbemalenograstim Alfa (third generation long-acting G-CSF)”, “Penpulimab (Anti PD-1)”, and innovative pipelines under development “FS222 (PD-L1/CD137 bispecific antibody)”, “Benmelstobart (Anti PD-L1)”, “TQB3617 (BET inhibitor)”, “TQB3728 (IAP antagonist)”, “TQB2930 (HER2 bispecific antibody)” and others will present 52 latest research results at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, covering clinical research and basic research on multiple types of cancers, such as osteosarcomas and soft tissue sarcomas, lung cancers, head and neck cancers, digestive system tumors, gynecologic cancers, breast cancers and malignant tumors.

**TWO ORAL SESSIONS**

1. First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma

Session Type: Oral

Corresponding Author: Clinica Universidad de Navarra, Spain, Ignacio Melero Bermejo

First Author: Vall d’Hebron University Hospital (HUVH) and Vall d’Hebron Institute of Oncology (VHIO), Spain, Elena Garralda

2. A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts  
Session Type: Rapid Oral  
Corresponding Author: Peking University Cancer Hospital & Institute, Jiayong Liu  
First Author: Peking University Cancer Hospital & Institute, Zhichao Tan

## **OTHER SESSION TYPES**

### **Osteosarcomas and soft tissue sarcomas:**

3. Updated results from ALTER-S002: A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIB classic osteosarcoma of the extremity  
Session Type: Poster  
Corresponding Author: West China Hospital, Sichuan University, Chongqi Tu  
First Author: West China Hospital, Sichuan University, Fan Tang
4. Anlotinib versus placebo as adjuvant therapy for completely resected high-grade soft tissue sarcomas: Interim results of a phase 2, double-blinded, randomized controlled trial  
Session Type: Poster  
Corresponding Author: Fudan University Shanghai Cancer Center, Wangjun Yan  
First Author: Fudan University Shanghai Cancer Center, Chun-Meng Wang
5. Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study  
Session Type: Poster  
Corresponding Author: West China Hospital, Sichuan University, Yu Jiang  
First Author: West China Hospital, Sichuan University, Jie Liu
6. An open label, phase 1b/2 trial of LVGN6051 (4-1BB agonistic antibody) combined with anlotinib for refractory soft tissue sarcoma (STS)  
Session Type: Poster  
Corresponding Author: Shanghai Sixth People's Hospital, Haiyan Hu  
First Author: Shanghai Sixth People's Hospital, Yan Zhou

7. Maintenance treatment with toripalimab and anlotinib after anthracycline-based chemotherapy in patients with advanced soft tissue sarcoma (TORAN): A single-arm, phase 2 trial  
Session Type: Poster  
Corresponding Author: West China Hospital, Sichuan University, Yu Jiang  
First Author: West China Hospital, Sichuan University, Yaotiao Deng

**Lung cancers:**

8. Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials  
Session Type: Poster  
Corresponding Author: Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Yong Fang  
First Author: Hunan Cancer Hospital, Lin Wu
9. MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy  
Session Type: Poster  
Corresponding Author: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Baohui Han  
First Author: Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Baohui Han
10. PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer  
Session Type: Publication  
First Author: Shandong Cancer Hospital and Institute, Jian Zhang
11. Meta-analysis of the efficacy and safety of anlotinib combined with chemotherapy in the treatment of small cell lung cancer  
Session Type: Publication  
Corresponding Author: Xianyang Central Hospital, Xiaopeng He  
First Author: Xianyang Central Hospital, Ting Gao

12. Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis  
Session Type: Publication  
Corresponding Author: Affiliated Cancer Hospital of Zhengzhou University, Yanqiu Zhao  
First Author: Affiliated Cancer Hospital of Zhengzhou University, Lijuan Chen
13. A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer  
Session Type: Publication  
Corresponding Author: First Affiliated Hospital of Guangdong Pharmaceutical University, Size Chen  
First Author: First Affiliated Hospital of Guangdong Pharmaceutical University, Size Chen

**Head and neck cancers:**

14. Long-term outcomes of anlotinib and penpulimab combined with chemotherapy in the treatment of patients with metastatic nasopharyngeal carcinoma that failed definitive platinum-based chemoradiotherapy  
Session Type: Poster  
Corresponding Author: Zhejiang Cancer Hospital, Xiaozhong Chen  
First Author: Zhejiang Cancer Hospital, Shuang Huang
15. Gemcitabine and cisplatin chemotherapy plus penpulimab combined with or without anlotinib as neoadjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A prospective, phase II clinical trial  
Session Type: Publication  
Corresponding Author: Sun Yat-sen University Cancer Center, Hai-Qiang Mai  
First Author: Sun Yat-sen University Cancer Center, Lin-Quan Tang
16. Efficacy and safety of anlotinib combined with sintilizumab in locally advanced or metastatic anaplastic thyroid carcinoma  
Session Type: Poster  
Corresponding Author: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Lin Gui  
First Author: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Haohua Zhu

17. Safety and efficacy of CyberKnife radiosurgery plus anlotinib hydrochloride in patients with recurrent glioblastoma: A prospective phase II single-arm study  
Session Type: Poster  
Corresponding Author: Huashan Hospital, Fudan University, Xin Wang  
First Author: Huashan Hospital, Fudan University, Yun Guan
  
18. Response-adaptive resection following neoadjuvant penpulimab combined with chemotherapy in HPV-negative operable locally advanced head and neck squamous cell: A phase II clinical trial  
Session Type: Publication  
Corresponding Author: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Kunyu Yang  
First Author: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Kunyu Yang

**Digestive system tumors:**

19. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial  
Session Type: Publication  
Corresponding Author: Henan Cancer Hospital, Suxia Luo  
First Author: Anyang Cancer Hospital, Junsheng Wang
  
20. Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial  
Session Type: Publication  
Corresponding Author: The First Affiliated Hospital of Zhengzhou University, Feng Wang  
First Author: The First Affiliated Hospital of Zhengzhou University, Xiangrui Meng
  
21. Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial  
Session Type: Publication  
Corresponding Author: The First Affiliated Hospital of Zhengzhou University, Yanru Qin  
First Author: The First Affiliated Hospital of Zhengzhou University, Zhiwei Chang

22. The feasibility and tolerability of anlotinib plus PD-1 blockades among patients with previously immunotherapy treated advanced esophageal squamous cell carcinoma (ESCC): Update results of a retrospective exploratory study  
Session Type: Publication  
Corresponding Author: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Jing Huang  
First Author: National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Jing Huang
23. Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial  
Session Type: Publication  
Corresponding Author: West China Hospital, Sichuan University, Zhen-Yu Ding  
First Author: West China Hospital, Sichuan University, Yueyun Chen
24. Irinotecan plus anlotinib or further in combination with penpulimab as second-line treatment of metastatic colorectal cancer (ZL-IRIAN)  
Session Type: Poster  
Corresponding Author: Fudan University Shanghai Cancer Center, Weijian Guo  
First Author: Fudan University Shanghai Cancer Center, Chenchen Wang
25. Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study  
Session Type: Poster  
Corresponding Author: Nanjing Drum Tower Hospital, Baorui Liu & Nanjing Drum Tower Hospital, Juan Du  
First Author: Nanjing Drum Tower Hospital, Juan Du
26. Tislelizumab with anlotinib and chemotherapy for second-line treatment of pancreatic ductal adenocarcinoma: A pilot study early result  
Session Type: Publication  
Corresponding Author: First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Enxiao Li  
First Author: First Affiliated Hospital of Medical College of Xi'an Jiaotong University, Xuyuan Dong

27. Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial  
Session Type: Publication  
Corresponding Author: The First Affiliated Hospital of Zhengzhou University, Hong Zong  
First Author: The First Affiliated Hospital of Zhengzhou University, Wen-Zhi Guo
28. Real-world study of anlotinib monotherapy and combination therapy for unresectable hepatocellular carcinoma  
Session Type: Publication  
Corresponding Author: Nanfang Hospital, Southern Medical University, Yun Zhu  
First Author: Nanfang Hospital, Southern Medical University, Yi Lei
29. Anlotinib plus chemotherapy as first-line therapy for patients with gastrointestinal tumor with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial, ALTER-G-001-cohort C  
Session Type: Publication  
Corresponding Author: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Jun Zhang  
First Author: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Junwei Wu

**Gynecologic cancers:**

30. Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinical trial (TQB2450-II-08)  
Session Type: Poster  
Corresponding Author: Fudan University Shanghai Cancer Center, Xiaohua Wu  
First Author: Fudan University Shanghai Cancer Center, Xiaohua Wu

31. Anlotinib plus hormone therapy in patients with platinum-resistant recurrent ovarian cancer: A prospective, single-arm, open-label, phase II study  
Session Type: Poster  
Corresponding Author: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Xipeng Wang  
First Author: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Xipeng Wang
32. A phase II study of anlotinib plus albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or peritoneal carcinoma (A-Plus trial): Updated efficacy and safety  
Session Type: Poster  
Corresponding Author: Sun Yat-sen University Cancer Center, Yanfang Li  
First Author: Sun Yat-sen University Cancer Center, Yanfang Li
33. A single-arm, phase II trial assessing the combination of AK105 and anlotinib in first-line treatment for persistent, recurrent, or metastatic cervical cancer  
Session Type: Poster  
Corresponding Author: The First Affiliated Hospital of Zhengzhou University, Ruixia Guo  
First Author: The First Affiliated Hospital of Zhengzhou University, Haifeng Qiu
34. Anlotinib combined with penpulimab as first-line treatment for persistent, recurrent, or metastatic cervical cancer: Preliminary results from ALTER-GO-020, a single-arm, open-label, multi-cohort, multi-center phase II clinical study  
Session Type: Publication  
Corresponding Author: Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Guonan Zhang  
First Author: Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Dengfeng Wang
35. Sintilimab and anlotinib combination therapy in PD-L1-positive recurrent/metastatic cervical carcinoma: A 3-year follow-up of ALTER-C201 study  
Session Type: Publication  
Corresponding Author: Fujian Provincial Cancer Hospital, Qin Xu  
First Author: Fujian Provincial Cancer Hospital, Qin Xu



36. Predictive value of C reactive protein (CRP) and D-dimer in patients with advanced cervical cancer treated with sintilimab and anlotinib  
Session Type: Publication  
Corresponding Author: Fujian Provincial Cancer Hospital, Qin Xu  
First Author: Fujian Provincial Cancer Hospital, Jing Liu

**Breast cancers:**

37. A Phase II Trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor-resistant, metastatic breast cancer  
Session Type: Publication  
Corresponding Author: Zhejiang Cancer Hospital, Xiaojia Wang  
First Author: Zhejiang Cancer Hospital, Jian Huang
38. The effects of anlotinib combined with chemotherapy following progression on cyclin-dependent kinase 4/6 inhibitor in hormone receptor-positive metastatic breast cancer  
Session Type: Publication  
Corresponding Author: Jiangsu Cancer Hospital, Lili Zhang  
First Author: Jiangsu Cancer Hospital, Ting Xu
39. A Phase II Trial of anlotinib combined chemotherapy as second-line and above therapy in HER2-negative advanced breast cancer  
Session Type: Publication  
Corresponding Author: Jiangsu Cancer Hospital, Lili Zhang  
First Author: Jiangsu Cancer Hospital, Yuan Yuan
40. The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL)  
Session Type: Publication  
Corresponding Author: Southwest Hospital, Army Medical University, Xiaowei Qi  
First Author: Southwest Hospital, Army Medical University, Wenting Yan

41. A multicenter real-world study on the efficacy and safety of anlotinib-based treatment for metastatic breast cancer  
Session Type: Publication  
First Author: The First Hospital of Jilin University, Xiang Li
42. Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: results from a phase 1b study  
Session Type: Poster  
Corresponding Author: Harbin Medical University Cancer Hospital, Qingyuan Zhang  
First Author: Harbin Medical University Cancer Hospital, Qingyuan Zhang

**Urinary system cancers:**

43. Updated results from a phase II study of penpulimab plus anlotinib as first-line therapy in metastatic urothelial cancer (mUC)  
Session Type: Poster  
Corresponding Author: Chinese PLA General Hospital, Bo Yang  
First Author: Chinese PLA General Hospital, Bo Yang
44. Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study  
Session Type: Poster  
Corresponding Author: Sun Yat-sen University Cancer Center, Pei Dong  
First Author: Sun Yat-sen University Cancer Center, Pei Dong
45. Anlotinib plus everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma: A single-center, single-arm, phase II trial  
Session Type: Publication  
Corresponding Author: Fudan University Shanghai Cancer Center, Hailiang Zhang  
First Author: Fudan University Shanghai Cancer Center, Hailiang Zhang

**Skin cancers:**

46. The efficacy and safety of toripalimab combined with anlotinib in the first-line treatment of Chinese patients with metastatic melanoma  
Session Type: Poster  
Corresponding Author: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jing Chen  
First Author: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Ting Ye
47. First-line of penpulimab and chemotherapy for advanced non-melanoma cutaneous carcinoma: A single center, single arm, exploratory study  
Session Type: Publication  
Corresponding Author: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Dongyuan Zhu  
First Author: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jing Xu

**Malignant tumors:**

48. First-in-human study of TQB3617, a BET inhibitor in patients with relapsed/refractory hematologic malignancies  
Session Type: Poster  
Corresponding Author: Sun Yat-sen University Cancer Center, Qingqing Cai  
First Author: Sun Yat-sen University Cancer Center, Qingqing Cai
49. Phase I study of TQB3728 tablets, an oral inhibitor of apoptosis proteins in patients with advanced solid tumor  
Session Type: Publication  
Corresponding Author: Sun Yat-sen University Cancer Center, Shusen Wang  
First Author: Sun Yat-sen University Cancer Center, Qiufan Zheng

**Neutropenia**

50. Guard 01: A randomized, multicentre, controlled trial on the prophylactic use of efbemalenograstim alfa for concurrent chemo-radiotherapy induced neutropenia  
Session Type: Poster  
Corresponding Author: Sun Yat-sen University Cancer Center, Ming Chen  
First Author: Sun Yat-sen University Cancer Center, Yuanyuan Chen

**Basic research:**

51. FGF19-FGFR4 axis as the inaugural target for determining the efficacy of advanced esophageal cancer treatment

Session Type: Poster

Corresponding Author: Nanfang Hospital, Southern Medical University, Wei Wang

First Author: Nanfang Hospital, Southern Medical University, Wei Wang

52. Multi-omics study on the molecular mechanism of anlotinib in regulating tumor metabolism

Session Type: Publication

Corresponding Author: Nanjing University of Chinese Medicine, Xiaoman Li

First Author: China Pharmaceutical University, Yu Lu

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 29 April 2024

*As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*